Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Calgary
$27,000.00
Renal Inflammation Evaluation Using Complement Activation Products and CD163 Tests
EF 2025-26
Résumé
Lupus nephritis (LN) and renal ANCA-associated vasculitis (rAAV) are serious autoimmune diseases causing kidney inflammation and damage that, if untreated, can lead to kidney failure, increased risk of cardiovascular problems, infections, and death. Kidney biopsy is the gold-standard for diagnosing LN and rAAV, but is invasive, carries risks like bleeding, and is not available everywhere. Blood and urine biomarkers, such as proteinuria, creatinine, and autoantibody levels are used as less invasive substitutes, but lack sufficient sensitivity or specificity for detecting renal inflammation. Further, no reliable biomarker currently predicts future LN or rAAV onset or guides safe therapy tapering in LN patients in remission.
Our study will evaluate specific immune proteins in the urine: urine-soluble CD163 (usCD163), urine complement activation products (uCAPS: C3a, C5a, and sC5b9), and SIGLEC-1, as accurate, non-invasive kidney inflammation markers. We will enroll LN and rAAV patients with recent biopsies and collect serial urine samples over a year to track biomarker changes while on treatment. Urine from systemic lupus erythematosus patients without known LN will be collected to assess if the urinary biomarkers can predict LN development. Finally, we will collect urine samples from LN patients in remission for at least two years starting to lower their immune-suppressing drugs.
These biomarkers will be checked for stability on dried urine strips to assess their use in portable testing for people in Indigenous and underserved communities lacking the same access to specialized kidney care. By validating and characterizing these urine biomarkers, our study aims to provide a safer, faster, and more accessible way to detect and monitor autoimmune kidney disease.
Activity details
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
573111
Name
Alkadri Sajida A
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Renal Inflammation Evaluation Using Complement Activation Products and CD163 Tests
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Anca-Associated Vasculitis; Autoimmunity; Glomerulonephritis; Liquid Biopsy; Lupus Nephritis; Non-Invasive Diagnostics; Precision Medicine; Renal Inflammation; Rheumatology; Urinary Biomarkers
Abstract
Lupus nephritis (LN) and renal ANCA-associated vasculitis (rAAV) are serious autoimmune diseases causing kidney inflammation and damage that, if untreated, can lead to kidney failure, increased risk of cardiovascular problems, infections, and death. Kidney biopsy is the gold-standard for diagnosing LN and rAAV, but is invasive, carries risks like bleeding, and is not available everywhere. Blood and urine biomarkers, such as proteinuria, creatinine, and autoantibody levels are used as less invasive substitutes, but lack sufficient sensitivity or specificity for detecting renal inflammation. Further, no reliable biomarker currently predicts future LN or rAAV onset or guides safe therapy tapering in LN patients in remission.
Our study will evaluate specific immune proteins in the urine: urine-soluble CD163 (usCD163), urine complement activation products (uCAPS: C3a, C5a, and sC5b9), and SIGLEC-1, as accurate, non-invasive kidney inflammation markers. We will enroll LN and rAAV patients with recent biopsies and collect serial urine samples over a year to track biomarker changes while on treatment. Urine from systemic lupus erythematosus patients without known LN will be collected to assess if the urinary biomarkers can predict LN development. Finally, we will collect urine samples from LN patients in remission for at least two years starting to lower their immune-suppressing drugs.
These biomarkers will be checked for stability on dried urine strips to assess their use in portable testing for people in Indigenous and underserved communities lacking the same access to specialized kidney care. By validating and characterizing these urine biomarkers, our study aims to provide a safer, faster, and more accessible way to detect and monitor autoimmune kidney disease.
Activity details
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Alkadri, Sajida A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~